| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioblastoma | 20 | 2022 | 219 | 6.410 |
Why?
|
| Brain Neoplasms | 15 | 2022 | 371 | 4.990 |
Why?
|
| Apoptosis | 34 | 2020 | 1640 | 4.230 |
Why?
|
| Meningioma | 5 | 2021 | 54 | 3.370 |
Why?
|
| Calpain | 20 | 2016 | 205 | 2.210 |
Why?
|
| Meningeal Neoplasms | 3 | 2021 | 42 | 2.210 |
Why?
|
| Cell Line, Tumor | 19 | 2020 | 1849 | 1.720 |
Why?
|
| Motor Neurons | 7 | 2016 | 98 | 1.600 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2020 | 194 | 1.540 |
Why?
|
| Allyl Compounds | 4 | 2018 | 29 | 1.450 |
Why?
|
| Caspases | 8 | 2015 | 194 | 1.260 |
Why?
|
| Lanosterol | 2 | 2019 | 11 | 1.250 |
Why?
|
| Heptanoic Acids | 2 | 2019 | 28 | 1.240 |
Why?
|
| Astrocytes | 7 | 2020 | 270 | 1.220 |
Why?
|
| Sulfides | 4 | 2018 | 43 | 1.210 |
Why?
|
| Triterpenes | 2 | 2019 | 40 | 1.210 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 2020 | 57 | 1.180 |
Why?
|
| Dipeptides | 9 | 2016 | 89 | 1.130 |
Why?
|
| Neuroprotective Agents | 13 | 2016 | 317 | 1.110 |
Why?
|
| Glutamic Acid | 4 | 2012 | 332 | 1.100 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2018 | 116 | 1.090 |
Why?
|
| Telomerase | 5 | 2009 | 85 | 1.070 |
Why?
|
| Histone Deacetylases | 2 | 2018 | 99 | 1.040 |
Why?
|
| Estrogens | 10 | 2022 | 173 | 0.990 |
Why?
|
| Flavonoids | 4 | 2012 | 109 | 0.980 |
Why?
|
| DNA Modification Methylases | 3 | 2020 | 24 | 0.980 |
Why?
|
| bcl-2-Associated X Protein | 12 | 2020 | 111 | 0.960 |
Why?
|
| DNA Repair Enzymes | 3 | 2020 | 53 | 0.960 |
Why?
|
| Cyclin-Dependent Kinase 6 | 2 | 2020 | 27 | 0.940 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2020 | 34 | 0.930 |
Why?
|
| Neurons | 6 | 2020 | 881 | 0.900 |
Why?
|
| Benzimidazoles | 2 | 2020 | 128 | 0.870 |
Why?
|
| Melatonin | 4 | 2010 | 39 | 0.850 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2020 | 756 | 0.840 |
Why?
|
| Interferon-gamma | 8 | 2011 | 241 | 0.810 |
Why?
|
| Receptors, Melatonin | 2 | 2012 | 8 | 0.810 |
Why?
|
| High Mobility Group Proteins | 1 | 2021 | 7 | 0.790 |
Why?
|
| Ependymoma | 1 | 2021 | 13 | 0.790 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2021 | 18 | 0.790 |
Why?
|
| Retinoids | 5 | 2012 | 122 | 0.780 |
Why?
|
| Neurofibromin 2 | 1 | 2020 | 10 | 0.750 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2020 | 14 | 0.750 |
Why?
|
| Spinal Cord Injuries | 10 | 2022 | 551 | 0.750 |
Why?
|
| Mediator Complex | 1 | 2020 | 5 | 0.750 |
Why?
|
| Neuroblastoma | 4 | 2010 | 109 | 0.740 |
Why?
|
| Oxidative Stress | 3 | 2010 | 718 | 0.730 |
Why?
|
| Quinolones | 1 | 2020 | 60 | 0.710 |
Why?
|
| Caspase 3 | 9 | 2020 | 233 | 0.710 |
Why?
|
| Calcium | 10 | 2012 | 929 | 0.710 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2020 | 79 | 0.710 |
Why?
|
| Animals | 39 | 2022 | 20877 | 0.700 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 100 | 0.700 |
Why?
|
| Cell Survival | 9 | 2020 | 901 | 0.690 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 2020 | 222 | 0.690 |
Why?
|
| Blotting, Western | 14 | 2015 | 954 | 0.680 |
Why?
|
| Glioma | 1 | 2020 | 140 | 0.680 |
Why?
|
| Piperazines | 1 | 2020 | 206 | 0.660 |
Why?
|
| Spinal Cord | 8 | 2022 | 244 | 0.660 |
Why?
|
| Antineoplastic Agents | 3 | 2020 | 1070 | 0.650 |
Why?
|
| Cell Differentiation | 5 | 2009 | 1034 | 0.650 |
Why?
|
| Pyridines | 1 | 2020 | 261 | 0.640 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2011 | 626 | 0.630 |
Why?
|
| Reactive Oxygen Species | 6 | 2016 | 499 | 0.620 |
Why?
|
| Rats | 23 | 2022 | 5300 | 0.610 |
Why?
|
| Radiation | 1 | 2016 | 7 | 0.590 |
Why?
|
| Medulloblastoma | 1 | 2016 | 24 | 0.580 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 11 | 2012 | 174 | 0.580 |
Why?
|
| Dexamethasone | 3 | 2017 | 150 | 0.580 |
Why?
|
| Dacarbazine | 2 | 2008 | 32 | 0.580 |
Why?
|
| HLA Antigens | 1 | 2016 | 82 | 0.580 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 4 | 2012 | 133 | 0.570 |
Why?
|
| Humans | 37 | 2022 | 68525 | 0.560 |
Why?
|
| Signal Transduction | 11 | 2020 | 2688 | 0.560 |
Why?
|
| Optic Neuritis | 2 | 2012 | 26 | 0.540 |
Why?
|
| Nerve Degeneration | 5 | 2012 | 134 | 0.530 |
Why?
|
| Limonins | 1 | 2015 | 10 | 0.530 |
Why?
|
| Catechols | 1 | 2015 | 14 | 0.530 |
Why?
|
| Flavones | 1 | 2015 | 11 | 0.530 |
Why?
|
| Fatty Alcohols | 1 | 2015 | 14 | 0.520 |
Why?
|
| Sesquiterpenes | 1 | 2015 | 41 | 0.520 |
Why?
|
| Caspase 8 | 6 | 2010 | 40 | 0.510 |
Why?
|
| Enzyme Activation | 8 | 2016 | 791 | 0.490 |
Why?
|
| Cell Death | 6 | 2019 | 329 | 0.490 |
Why?
|
| Antibodies, Monoclonal | 1 | 2016 | 510 | 0.480 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2019 | 304 | 0.460 |
Why?
|
| Cell Line | 7 | 2021 | 1752 | 0.460 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 163 | 0.460 |
Why?
|
| Inflammation | 11 | 2022 | 1030 | 0.450 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2013 | 33 | 0.450 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 467 | 0.450 |
Why?
|
| Mice, SCID | 3 | 2019 | 238 | 0.440 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2013 | 100 | 0.440 |
Why?
|
| Optic Nerve | 1 | 2012 | 55 | 0.430 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2020 | 331 | 0.430 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2020 | 99 | 0.420 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2020 | 332 | 0.410 |
Why?
|
| Down-Regulation | 5 | 2019 | 447 | 0.400 |
Why?
|
| Glycoproteins | 1 | 2012 | 238 | 0.400 |
Why?
|
| Sodium Channel Blockers | 1 | 2010 | 23 | 0.390 |
Why?
|
| Kainic Acid | 1 | 2010 | 44 | 0.390 |
Why?
|
| Ion Channel Gating | 1 | 2010 | 42 | 0.380 |
Why?
|
| Estradiol | 5 | 2022 | 176 | 0.370 |
Why?
|
| Paclitaxel | 2 | 2007 | 140 | 0.370 |
Why?
|
| Receptors, Estrogen | 1 | 2010 | 142 | 0.370 |
Why?
|
| Retinal Ganglion Cells | 2 | 2011 | 72 | 0.360 |
Why?
|
| Microglia | 5 | 2016 | 143 | 0.360 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 4 | 2010 | 22 | 0.350 |
Why?
|
| Apoptosis Regulatory Proteins | 4 | 2013 | 100 | 0.350 |
Why?
|
| Demyelinating Diseases | 2 | 2009 | 57 | 0.340 |
Why?
|
| Analysis of Variance | 6 | 2016 | 1039 | 0.340 |
Why?
|
| Mitochondria | 7 | 2011 | 643 | 0.340 |
Why?
|
| Cell Proliferation | 5 | 2020 | 1173 | 0.340 |
Why?
|
| Garlic | 2 | 2012 | 12 | 0.340 |
Why?
|
| Cysteine Proteinase Inhibitors | 6 | 2016 | 73 | 0.340 |
Why?
|
| Mice | 8 | 2020 | 8472 | 0.340 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2009 | 90 | 0.330 |
Why?
|
| NF-kappa B | 5 | 2016 | 432 | 0.330 |
Why?
|
| Acetazolamide | 1 | 2008 | 8 | 0.330 |
Why?
|
| Fenretinide | 1 | 2008 | 26 | 0.320 |
Why?
|
| Neurodegenerative Diseases | 3 | 2022 | 102 | 0.320 |
Why?
|
| Cells, Cultured | 7 | 2020 | 2673 | 0.320 |
Why?
|
| Methylprednisolone | 2 | 2011 | 99 | 0.320 |
Why?
|
| DNA Fragmentation | 4 | 2015 | 85 | 0.310 |
Why?
|
| RNA, Messenger | 4 | 2020 | 1663 | 0.310 |
Why?
|
| Gene Knockdown Techniques | 3 | 2019 | 196 | 0.310 |
Why?
|
| Cysteine Endopeptidases | 1 | 2007 | 39 | 0.310 |
Why?
|
| Hippocampus | 1 | 2010 | 471 | 0.300 |
Why?
|
| Phosphorylation | 4 | 2019 | 1199 | 0.300 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2007 | 88 | 0.300 |
Why?
|
| Gliosis | 4 | 2016 | 51 | 0.300 |
Why?
|
| Indomethacin | 1 | 2007 | 107 | 0.300 |
Why?
|
| Benzamides | 2 | 2020 | 156 | 0.290 |
Why?
|
| RNA | 2 | 2022 | 171 | 0.290 |
Why?
|
| Disease Models, Animal | 9 | 2022 | 2550 | 0.290 |
Why?
|
| Receptor, Melatonin, MT1 | 3 | 2012 | 10 | 0.290 |
Why?
|
| Receptor, Melatonin, MT2 | 3 | 2012 | 11 | 0.280 |
Why?
|
| In Situ Nick-End Labeling | 6 | 2013 | 160 | 0.280 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2007 | 250 | 0.280 |
Why?
|
| Pyrazoles | 3 | 2020 | 190 | 0.280 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2008 | 710 | 0.280 |
Why?
|
| Recovery of Function | 4 | 2022 | 506 | 0.270 |
Why?
|
| Glial Fibrillary Acidic Protein | 3 | 2012 | 92 | 0.270 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2018 | 1745 | 0.260 |
Why?
|
| Axons | 5 | 2022 | 139 | 0.250 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2020 | 331 | 0.250 |
Why?
|
| Cytochromes c | 4 | 2011 | 75 | 0.240 |
Why?
|
| Rats, Inbred Lew | 4 | 2012 | 150 | 0.240 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2022 | 12 | 0.210 |
Why?
|
| Preservation, Biological | 1 | 2022 | 11 | 0.210 |
Why?
|
| Cell Cycle | 2 | 2020 | 312 | 0.210 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2020 | 71 | 0.210 |
Why?
|
| Tumor Cells, Cultured | 4 | 2020 | 852 | 0.210 |
Why?
|
| Cytokines | 5 | 2012 | 866 | 0.210 |
Why?
|
| Tissue Preservation | 1 | 2022 | 44 | 0.210 |
Why?
|
| Necrosis | 2 | 2015 | 239 | 0.210 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2016 | 219 | 0.210 |
Why?
|
| Rats, Sprague-Dawley | 9 | 2022 | 2083 | 0.200 |
Why?
|
| Myelin Basic Protein | 2 | 2012 | 62 | 0.200 |
Why?
|
| Colorimetry | 3 | 2010 | 22 | 0.200 |
Why?
|
| Protein Domains | 1 | 2021 | 74 | 0.190 |
Why?
|
| Myoblasts | 2 | 2011 | 22 | 0.190 |
Why?
|
| G1 Phase Cell Cycle Checkpoints | 1 | 2020 | 12 | 0.190 |
Why?
|
| Cyclin D | 1 | 2020 | 12 | 0.190 |
Why?
|
| Smad Proteins | 1 | 2020 | 25 | 0.190 |
Why?
|
| Guanine | 1 | 2020 | 21 | 0.190 |
Why?
|
| Multiple Sclerosis | 3 | 2016 | 132 | 0.190 |
Why?
|
| Neuroprotection | 2 | 2022 | 28 | 0.190 |
Why?
|
| Sulfones | 1 | 2020 | 45 | 0.190 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2020 | 22 | 0.190 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2020 | 11 | 0.190 |
Why?
|
| Cloning, Molecular | 1 | 2021 | 357 | 0.190 |
Why?
|
| Aminopyridines | 1 | 2020 | 26 | 0.190 |
Why?
|
| bcl-X Protein | 1 | 2020 | 36 | 0.190 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 211 | 0.190 |
Why?
|
| Quinolines | 1 | 2020 | 48 | 0.190 |
Why?
|
| Triazines | 1 | 2020 | 48 | 0.180 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2020 | 282 | 0.180 |
Why?
|
| Wnt2 Protein | 1 | 2019 | 4 | 0.180 |
Why?
|
| Anaplasia | 1 | 2019 | 7 | 0.180 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2012 | 201 | 0.180 |
Why?
|
| Azacitidine | 1 | 2019 | 20 | 0.180 |
Why?
|
| Retinoblastoma Protein | 1 | 2020 | 75 | 0.180 |
Why?
|
| Locomotion | 2 | 2022 | 135 | 0.180 |
Why?
|
| Tamoxifen | 1 | 2020 | 62 | 0.180 |
Why?
|
| Imidazoles | 1 | 2020 | 175 | 0.180 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 110 | 0.180 |
Why?
|
| Membrane Potential, Mitochondrial | 2 | 2010 | 93 | 0.180 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2019 | 77 | 0.180 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 951 | 0.170 |
Why?
|
| Acid Ceramidase | 1 | 2020 | 85 | 0.170 |
Why?
|
| Pyrimidines | 1 | 2020 | 178 | 0.170 |
Why?
|
| Tretinoin | 3 | 2008 | 92 | 0.170 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 2 | 2010 | 17 | 0.170 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2019 | 118 | 0.170 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2019 | 160 | 0.170 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 170 | 0.170 |
Why?
|
| Cell Fusion | 2 | 2010 | 23 | 0.170 |
Why?
|
| Cell Membrane | 1 | 2020 | 523 | 0.160 |
Why?
|
| In Vitro Techniques | 1 | 2019 | 765 | 0.160 |
Why?
|
| Isotretinoin | 2 | 2008 | 8 | 0.160 |
Why?
|
| DNA Methylation | 1 | 2019 | 192 | 0.160 |
Why?
|
| Male | 12 | 2022 | 37281 | 0.160 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 799 | 0.160 |
Why?
|
| Drug Liberation | 1 | 2017 | 17 | 0.160 |
Why?
|
| Mitochondrial Proteins | 2 | 2008 | 113 | 0.150 |
Why?
|
| Epithelial Cells | 1 | 2020 | 431 | 0.150 |
Why?
|
| Pilot Projects | 1 | 2022 | 1341 | 0.150 |
Why?
|
| Promoter Regions, Genetic | 1 | 2019 | 614 | 0.150 |
Why?
|
| Cyclooxygenase 2 | 3 | 2012 | 160 | 0.150 |
Why?
|
| 4-1BB Ligand | 1 | 2016 | 5 | 0.150 |
Why?
|
| Drug Carriers | 1 | 2017 | 90 | 0.150 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2008 | 216 | 0.150 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2016 | 52 | 0.150 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2016 | 84 | 0.150 |
Why?
|
| Drug Interactions | 2 | 2008 | 289 | 0.140 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2016 | 15 | 0.140 |
Why?
|
| Ionomycin | 2 | 2006 | 24 | 0.140 |
Why?
|
| Ionophores | 2 | 2006 | 25 | 0.140 |
Why?
|
| Receptor, ErbB-2 | 1 | 2016 | 128 | 0.140 |
Why?
|
| Gene Expression Regulation | 2 | 2012 | 1293 | 0.140 |
Why?
|
| Gamma Rays | 1 | 2015 | 64 | 0.140 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2015 | 30 | 0.140 |
Why?
|
| Drug Delivery Systems | 1 | 2017 | 236 | 0.130 |
Why?
|
| Spectrin | 2 | 2005 | 17 | 0.130 |
Why?
|
| Patch-Clamp Techniques | 2 | 2006 | 204 | 0.130 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2015 | 57 | 0.130 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2015 | 64 | 0.130 |
Why?
|
| Radiation Injuries | 1 | 2015 | 97 | 0.130 |
Why?
|
| Mutation | 1 | 2020 | 1213 | 0.130 |
Why?
|
| Wnt Signaling Pathway | 1 | 2015 | 57 | 0.130 |
Why?
|
| Hydroxamic Acids | 1 | 2015 | 84 | 0.120 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2016 | 105 | 0.120 |
Why?
|
| Oligopeptides | 1 | 2015 | 152 | 0.120 |
Why?
|
| Nanoparticles | 1 | 2017 | 254 | 0.120 |
Why?
|
| Fatty Acids | 1 | 2015 | 222 | 0.120 |
Why?
|
| Nitriles | 2 | 2010 | 68 | 0.120 |
Why?
|
| Phenols | 2 | 2010 | 73 | 0.120 |
Why?
|
| RNA, Small Interfering | 2 | 2012 | 434 | 0.120 |
Why?
|
| Nerve Tissue Proteins | 2 | 2012 | 290 | 0.110 |
Why?
|
| Motor Activity | 2 | 2022 | 621 | 0.110 |
Why?
|
| Aquaporin 4 | 1 | 2012 | 3 | 0.110 |
Why?
|
| Calbindins | 1 | 2012 | 23 | 0.110 |
Why?
|
| Models, Biological | 2 | 2007 | 981 | 0.110 |
Why?
|
| Molecular Weight | 1 | 2012 | 358 | 0.110 |
Why?
|
| Parvalbumins | 1 | 2012 | 29 | 0.110 |
Why?
|
| Fluorescent Antibody Technique | 2 | 2010 | 282 | 0.100 |
Why?
|
| Time Factors | 3 | 2016 | 4655 | 0.100 |
Why?
|
| Cysteine Proteases | 1 | 2011 | 4 | 0.100 |
Why?
|
| Genistein | 1 | 2011 | 26 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 507 | 0.100 |
Why?
|
| Calcium-Binding Proteins | 2 | 2009 | 114 | 0.100 |
Why?
|
| Hybrid Cells | 1 | 2010 | 18 | 0.100 |
Why?
|
| Estrogen Receptor beta | 1 | 2010 | 19 | 0.100 |
Why?
|
| Calcium Channels, L-Type | 1 | 2010 | 34 | 0.100 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2012 | 167 | 0.100 |
Why?
|
| Tryptamines | 1 | 2010 | 7 | 0.090 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2012 | 138 | 0.090 |
Why?
|
| Membrane Potentials | 2 | 2011 | 200 | 0.090 |
Why?
|
| Embryo, Mammalian | 1 | 2010 | 176 | 0.090 |
Why?
|
| Estrogen Receptor alpha | 1 | 2010 | 65 | 0.090 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 1533 | 0.090 |
Why?
|
| Catechin | 1 | 2010 | 26 | 0.090 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 175 | 0.090 |
Why?
|
| Trauma, Nervous System | 1 | 2009 | 6 | 0.090 |
Why?
|
| Seizures | 1 | 2012 | 279 | 0.090 |
Why?
|
| Disease Progression | 1 | 2013 | 1037 | 0.090 |
Why?
|
| Brain | 1 | 2020 | 2175 | 0.090 |
Why?
|
| Hydrogen Peroxide | 1 | 2010 | 168 | 0.090 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2009 | 107 | 0.080 |
Why?
|
| Central Nervous System | 1 | 2009 | 107 | 0.080 |
Why?
|
| Time | 1 | 2008 | 57 | 0.080 |
Why?
|
| Aquaporin 1 | 1 | 2008 | 2 | 0.080 |
Why?
|
| Lipopolysaccharides | 1 | 2010 | 455 | 0.080 |
Why?
|
| Carbonic Anhydrases | 1 | 2008 | 18 | 0.080 |
Why?
|
| Drug Synergism | 1 | 2009 | 260 | 0.080 |
Why?
|
| Caspase 1 | 1 | 2008 | 22 | 0.080 |
Why?
|
| RNA, Neoplasm | 1 | 2008 | 76 | 0.080 |
Why?
|
| Brain Edema | 1 | 2008 | 50 | 0.080 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2008 | 111 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2007 | 20 | 0.080 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2007 | 60 | 0.080 |
Why?
|
| Disulfides | 1 | 2007 | 40 | 0.080 |
Why?
|
| Liver | 1 | 2013 | 1118 | 0.080 |
Why?
|
| Antioxidants | 1 | 2008 | 304 | 0.070 |
Why?
|
| Neoplasm Proteins | 1 | 2008 | 307 | 0.070 |
Why?
|
| Up-Regulation | 1 | 2008 | 682 | 0.070 |
Why?
|
| Recombinant Proteins | 1 | 2007 | 742 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2009 | 595 | 0.070 |
Why?
|
| Biomarkers | 1 | 2010 | 1593 | 0.060 |
Why?
|
| Middle Aged | 2 | 2020 | 21119 | 0.060 |
Why?
|
| Biomarkers, Tumor | 2 | 2020 | 508 | 0.060 |
Why?
|
| Aged | 1 | 2019 | 14842 | 0.060 |
Why?
|
| Cell Division | 1 | 2020 | 541 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2016 | 1329 | 0.040 |
Why?
|
| Albumins | 1 | 2017 | 72 | 0.040 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2017 | 85 | 0.040 |
Why?
|
| Solutions | 1 | 2017 | 115 | 0.040 |
Why?
|
| Survival Rate | 1 | 2020 | 1055 | 0.040 |
Why?
|
| Liposomes | 1 | 2017 | 107 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2016 | 56 | 0.040 |
Why?
|
| Carbamates | 1 | 2016 | 41 | 0.040 |
Why?
|
| Water | 1 | 2017 | 228 | 0.040 |
Why?
|
| Th1 Cells | 1 | 2016 | 101 | 0.030 |
Why?
|
| Kinetics | 1 | 2017 | 1047 | 0.030 |
Why?
|
| Lipids | 1 | 2017 | 298 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 196 | 0.030 |
Why?
|
| Th17 Cells | 1 | 2016 | 116 | 0.030 |
Why?
|
| Polymers | 1 | 2017 | 244 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 2016 | 142 | 0.030 |
Why?
|
| Prognosis | 1 | 2020 | 2093 | 0.030 |
Why?
|
| Mossy Fibers, Hippocampal | 1 | 2012 | 4 | 0.030 |
Why?
|
| Adenosine Kinase | 1 | 2012 | 6 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2012 | 37 | 0.030 |
Why?
|
| Sympathetic Nervous System | 1 | 2011 | 81 | 0.030 |
Why?
|
| Comprehension | 1 | 2012 | 71 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 64 | 0.030 |
Why?
|
| Caspase 9 | 1 | 2011 | 31 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 1 | 2011 | 89 | 0.030 |
Why?
|
| Myositis | 1 | 2011 | 24 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2012 | 84 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2012 | 120 | 0.020 |
Why?
|
| DNA Repair | 1 | 2012 | 127 | 0.020 |
Why?
|
| Estrogen Antagonists | 1 | 2010 | 10 | 0.020 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2011 | 24 | 0.020 |
Why?
|
| Tissue Embedding | 1 | 2010 | 4 | 0.020 |
Why?
|
| Flavoproteins | 1 | 2010 | 4 | 0.020 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2010 | 28 | 0.020 |
Why?
|
| I-kappa B Proteins | 1 | 2010 | 47 | 0.020 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2010 | 49 | 0.020 |
Why?
|
| Oligodendroglia | 1 | 2010 | 107 | 0.020 |
Why?
|
| Boron Compounds | 1 | 2009 | 21 | 0.020 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2009 | 67 | 0.020 |
Why?
|
| Acute Disease | 1 | 2011 | 658 | 0.020 |
Why?
|
| Indoles | 1 | 2010 | 146 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2011 | 562 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 848 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2009 | 306 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2012 | 447 | 0.020 |
Why?
|
| Macrophages | 1 | 2010 | 647 | 0.020 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2006 | 77 | 0.020 |
Why?
|
| Central Nervous System Depressants | 1 | 2007 | 182 | 0.020 |
Why?
|
| Female | 2 | 2020 | 38015 | 0.010 |
Why?
|
| United States | 1 | 2013 | 7335 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2011 | 7028 | 0.010 |
Why?
|